ArticleMethods in molecular biology (Clifton, N.J.)2026
Defining the Role of Marginal Zone B Cells in FVIII Inhibitor Development.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The formation of factor VIII (FVIII) inhibitors in hemophilia A patients involves complex immune responses, including the activation of CD4 T cells and B cells. Marginal zone (MZ) B cells, an innate-like B cell population in the spleen, play a key role in the early stages of inhibitor development by rapidly responding to blood-borne antigens. These cells are uniquely positioned to capture and present FVIII to CD4 T cells, initiating a robust immune response that can lead to the formation of neutralizing antibodies. This chapter explores the critical role of MZ B cells in FVIII inhibitor development, focusing on their function in antigen presentation and their potential as therapeutic targets to prevent inhibitor formation. Using immunohistochemistry (IHC) and flow cytometry, we investigate the interactions between MZ B cells, CD4 T cells, and other immune components in the spleen, providing a deeper understanding of the molecular mechanisms underlying FVIII inhibitor development. By elucidating these immune interactions, we aim to inform the development of novel strategies to mitigate FVIII inhibitor formation in hemophilia A patients.
Indexed as
Identifiers
42681453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.